News & Updates
Filter by Specialty:
Short-course, high-dose gatifloxacin gets a pass in multidrug-resistant TB with caveat
A short-term treatment regimen based on high-dose gatifloxacin appears to be effective against multidrug- or rifampicin-resistant tuberculosis (TB) but at the cost of increased severe adverse drug reactions, as shown in a study.
Short-course, high-dose gatifloxacin gets a pass in multidrug-resistant TB with caveat
08 Dec 2021
Ixekizumab effective for difficult-to-treat psoriatic arthritis
The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.
Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021
AECOPD outcomes unaltered with short-course nonmacrolide therapy
Short-course nonmacrolide therapy in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) appears to have no significant effect on outcomes including mortality, progression to ventilation, readmission rate, or prevalence of adverse drug events, a study has shown.
AECOPD outcomes unaltered with short-course nonmacrolide therapy
08 Dec 2021
Cholinesterase inhibitors show promise for treating gait disturbance in PD
Treatment with cholinesterase inhibitors in patients with Parkinson’s disease (PD) leads to significant improvements in gait variability, with trending benefits for gait speed and fall prevention, according to the results of a meta-analysis.